PYXS Pyxis Oncology (PYXS) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001782223
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
34
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $56.0K priced
What the filings say about PYXS
Insiders, 180 days
-$107.1K net sold
1 seller · 0% of sales under a 10b5-1 plan
Pyxis Oncology insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Pyxis Oncology, Inc. insiders sold a net $107.1K of stock across 25 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 90.3% of the 38,741 shares held after it.
- No other insider sold within 30 days.
- 34 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Dupont Jakob sold about $107.1K of PYXS on Jun 30, 2026, the largest insider sale at the company since 2022; 34 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Apr 17, 2025.
- The trade is 17.1% of the 81,309 shares held after it.
- No other insider sold within 30 days.
- 34 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director HUMPHREY RACHEL sold about $14.3K of PYXS on Apr 21, 2025, the largest insider sale at the company since 2023; 34 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Apr 14, 2025.
- The trade is 0.2% of the 95,205 shares held after it.
- No other insider sold within 30 days.
- 34 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director HUMPHREY RACHEL sold about $194 of PYXS on Apr 17, 2025; 34 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 1.5% of the 95,405 shares held after it.
- No other insider sold within 30 days.
- 34 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director HUMPHREY RACHEL sold about $1.4K of PYXS on Apr 14, 2025, the largest insider sale at the company since 2023; 34 funds added in the latest 13F quarter.25 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$107.1K over 180 days
more than 55% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
34 funds bought in last quarter
below 60% of Pharma & Biotech
Revenue
-14.2% year over year
below 67% of Pharma & Biotech
Margin
-574.5% net margin
below 79% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
7.9% of the float short (float per yahoo 2026-10-27) · 3.5 days to cover · settled 2026-10-15
more than 52% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch PYXS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-50.0%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PYXS: institutional holders (13F)
13F holdings, latest reported quarter
10,024,909 sh
$30.2M
7,032,770 sh
$19.5M
4,900,888 sh
$14.8M
2,075,997 sh
$6.2M
1,728,554 sh
$5.2M
Congress trades in PYXS
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PYXS planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Dupont Jakob
Filed 2026-06-30
$107.0K
PYXS mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$210.9K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$501.4K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$33.7K position · as of 2026-06-30
0.0%
iShares Biotechnology ETF
$1.1M position · as of 2026-06-30
0.0%
Invesco Nasdaq Biotechnology ETF
$5.9K position · as of 2026-05-31
0.0%
ProShares Ultra Nasdaq Biotechnology
$4.1K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 1
2 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $107.1K sold by insiders over 180 days, 34 funds added last quarter. Each figure is a federal filing, dated the day it went public.
PYXS financials
Revenue growth
-14.2%
XBRL, annual
Net margin
-574.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM PYXS
| FY Dec 2025 | n/a |
| FY Dec 2024 | $16.1M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | $11.0M |
| Sep 2025 | $0 |
| Jun 2025 | $2.8M |
| Mar 2025 | n/a |
| Dec 2024 | $0 |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM PYXS
| FY Dec 2025 | n/a |
| FY Dec 2024 | -478.9% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -164.0% |
| Sep 2025 | n/a |
| Jun 2025 | -650.9% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM PYXS
| FY Dec 2025 | n/a |
| FY Dec 2024 | -$57.9M |
| FY Dec 2023 | -$77.4M |
| FY Dec 2022 | -$95.7M |
| FY Dec 2021 | -$35.9M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -$10.4M |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$19.3M |
| Sep 2024 | -$14.7M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity PYXS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt PYXS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-179.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PYXS
| FY Dec 2025 | -91.4% |
| FY Dec 2024 | -62.8% |
| FY Dec 2023 | -51.5% |
| FY Dec 2022 | -57.2% |
| FY Dec 2021 | -61.9% |
| Jun 2026 | -179.1% |
| Mar 2026 | -121.7% |
| Dec 2025 | -91.4% |
| Sep 2025 | -87.3% |
| Jun 2025 | -74.8% |
| Mar 2025 | -66.3% |
| Dec 2024 | -62.8% |
| Sep 2024 | -39.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-99.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PYXS
| FY Dec 2025 | -64.0% |
| FY Dec 2024 | -46.7% |
| FY Dec 2023 | -38.3% |
| FY Dec 2022 | -49.1% |
| FY Dec 2021 | -52.4% |
| Jun 2026 | -99.6% |
| Mar 2026 | -81.7% |
| Dec 2025 | -64.0% |
| Sep 2025 | -64.5% |
| Jun 2025 | -58.1% |
| Mar 2025 | -53.5% |
| Dec 2024 | -46.7% |
| Sep 2024 | -30.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital PYXS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-138.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PYXS
| FY Dec 2025 | -80.4% |
| FY Dec 2024 | -62.2% |
| FY Dec 2023 | -50.2% |
| FY Dec 2022 | -56.0% |
| FY Dec 2021 | -52.1% |
| Jun 2026 | -138.5% |
| Mar 2026 | -101.5% |
| Dec 2025 | -80.4% |
| Sep 2025 | -81.3% |
| Jun 2025 | -71.7% |
| Mar 2025 | -65.2% |
| Dec 2024 | -62.2% |
| Sep 2024 | -40.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing PYXS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value PYXS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield PYXS
| FY Dec 2025 | n/a |
| FY Dec 2024 | -62.4% |
| FY Dec 2023 | -97.1% |
| FY Dec 2022 | -203.6% |
| FY Dec 2021 | -10.0% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -52.7% |
| Jun 2025 | -108.6% |
| Mar 2025 | -99.0% |
| Dec 2024 | -62.4% |
| Sep 2024 | -24.9% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing PYXS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $13.9M | $16.1M | n/a | n/a |
| Operating income | -$84.4M | -$89.5M | -$82.2M | -$123.5M |
| Net income | -$79.6M | -$77.3M | -$73.8M | -$120.7M |
| EPS (diluted) | -1.28 | -1.32 | -1.85 | -3.65 |
| Operating cash flow | -$63.5M | -$57.7M | -$70.7M | -$89.3M |
| Cash | $15.4M | $19.5M | $9.7M | $179.3M |
SEC XBRL, fiscal years, as known on 2026-10-28
PYXS Stock Sonar score 5/7 axes
Find similar shapesComparePYXS ranks highest on risk and compliance (55th percentile) and institutional and government (40th), and lowest on profitability (20th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
PYXS filings, in plain words
Are Pyxis Oncology insiders buying or selling PYXS?
In the 180 days to 2026-10-28, Pyxis Oncology insiders were net sellers, a net $107.1K across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-28, Pyxis Oncology insiders were net sellers of PYXS, a net $107.1K across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
